🎙️ Just published a new episode of Blood Podcast: New Research: Mitochondrial DNA in TRALI and Venetoclax-Obinituzumab in CLL Trials. Have a listen:
New Research: Mitochondrial DNA in TRALI and Venetoclax-Obinituzumab in CLL Trials
In this week's episode, associate editor Dr. James Griffin interviews...
bloodpodcast.transistor.fm
November 13, 2025 at 5:00 PM
🎙️ Just published a new episode of Blood Podcast: New Research: Mitochondrial DNA in TRALI and Venetoclax-Obinituzumab in CLL Trials. Have a listen:
Obinituzumab aka ‘Obi’ is now FDA approved for lupus nephritis
finance.yahoo.com/news/fda-app...
#lupus
finance.yahoo.com/news/fda-app...
#lupus
FDA Approves Genentech’s Gazyva for the Treatment of Lupus Nephritis
SOUTH SAN FRANCISCO, Calif., October 20, 2025--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved Gazyva...
finance.yahoo.com
October 20, 2025 at 11:14 AM
Obinituzumab aka ‘Obi’ is now FDA approved for lupus nephritis
finance.yahoo.com/news/fda-app...
#lupus
finance.yahoo.com/news/fda-app...
#lupus
Great talk by our very own Dr. Brad Rovin @OhioStateNeph on LN therapies! Yes to Obinituzumab vis REGENCY. Belimumab works but may not all the way. And maybe CAR-T is the future!! Also keep HCQ going 🙏🏽
April 11, 2025 at 3:37 PM
Great talk by our very own Dr. Brad Rovin @OhioStateNeph on LN therapies! Yes to Obinituzumab vis REGENCY. Belimumab works but may not all the way. And maybe CAR-T is the future!! Also keep HCQ going 🙏🏽
Obinituzumab in NL in NEJM 2025.
But… complete renal response 30.9% in the placebo group?
www.nejm.org/doi/full/10....
But… complete renal response 30.9% in the placebo group?
www.nejm.org/doi/full/10....
Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis | NEJM
Obinutuzumab, a humanized type II anti-CD20 monoclonal antibody, provided significantly better renal responses than placebo in a phase 2 trial involving patients with lupus nephritis receiving stan...
www.nejm.org
February 8, 2025 at 6:31 PM
Obinituzumab in NL in NEJM 2025.
But… complete renal response 30.9% in the placebo group?
www.nejm.org/doi/full/10....
But… complete renal response 30.9% in the placebo group?
www.nejm.org/doi/full/10....
Difference btwn obinituzumab and rituxan is dosing schedule. 2 doses of obinituzumab at time 0, 6 mo, 12 mo is double 6 and 12 mo dose of rituxan.
Believe obinituzumab has better depletion than rituxan, but wonder how much of it is dose effect.
Why not give more rituxan? Its generic.
Believe obinituzumab has better depletion than rituxan, but wonder how much of it is dose effect.
Why not give more rituxan? Its generic.
February 7, 2025 at 2:15 PM
Difference btwn obinituzumab and rituxan is dosing schedule. 2 doses of obinituzumab at time 0, 6 mo, 12 mo is double 6 and 12 mo dose of rituxan.
Believe obinituzumab has better depletion than rituxan, but wonder how much of it is dose effect.
Why not give more rituxan? Its generic.
Believe obinituzumab has better depletion than rituxan, but wonder how much of it is dose effect.
Why not give more rituxan? Its generic.
🧵 below
@nejm.org paper here: www.nejm.org/doi/full/10....
#ISNWCN LBCT of #obinituzumab in lupus nephritis
#SLE
@nejm.org paper here: www.nejm.org/doi/full/10....
#ISNWCN LBCT of #obinituzumab in lupus nephritis
#SLE
February 7, 2025 at 12:06 PM
🧵 below
@nejm.org paper here: www.nejm.org/doi/full/10....
#ISNWCN LBCT of #obinituzumab in lupus nephritis
#SLE
@nejm.org paper here: www.nejm.org/doi/full/10....
#ISNWCN LBCT of #obinituzumab in lupus nephritis
#SLE
February 7, 2025 at 9:34 AM
